title: Novel treatments for chronic lymphocytic leukemia and moving forward.
abstract: The last several years have seen an explosion of novel therapies for chronic lymphocytic leukemia (CLL). These include the antibody obintutuzumab (GA-101), as well as small-molecule inhibitors of key pathways involved in the pathogenesis of CLL, specifically the B-cell receptor (BCR) pathway (especially Bruton's tyrosine kinase [BTK] and P13K), and the antiapoptotic pathway (especially BCL-2). We will consider each in turn, focusing on the molecules most advanced in clinical development. There has also been extensive development in rewiring the patient's own immune system to treat CLL. This has been done through modifying autologous T cells to express a chimeric antigen receptor (CAR). Thus far all CAR-T preparations have targeted the CD19 antigen. This is a good rational for B-cell malignancies as CD19 expression is limited to B-cell malignancies and normal B cells. The in vivo amplification of the transduced T cells relies on signaling and co-signaling domains and provides significant killing of CLL cells. As exciting as these novel agents and approaches are, they obviously beg the question, will chemotherapy as a treatment for CLL soon be obsolete? Although chemotherapy is associated with known short-term toxicities, it has the advantage of being completed in a short period of time and being relatively inexpensive in comparison to novel therapies. In addition, long-term follow-up of results with chemoimmunotherapy have now identified a group of patients whose remissions are maintained for more than 10 years. An important question that will arise going forward is how to incorporate novel agents without eliminating the long term benefits possible with chemoimmunotherapy in a subset of patients with CLL.
authors.affiliation: From the Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Boston, MA; Blood and Marrow Transplantation, Hospital of the University of Pennsylvania, Philadelphia, PA; Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: Jennifer R
authors.initials: JR
authors.lastname: Brown
authors.affiliation: From the Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Boston, MA; Blood and Marrow Transplantation, Hospital of the University of Pennsylvania, Philadelphia, PA; Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: David L
authors.initials: DL
authors.lastname: Porter
authors.affiliation: From the Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Boston, MA; Blood and Marrow Transplantation, Hospital of the University of Pennsylvania, Philadelphia, PA; Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: Susan M
authors.initials: SM
authors.lastname: O'Brien
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000077329:Agammaglobulinaemia Tyrosine Kinase; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology; D018941:Antigens, CD19 / Q000235:genetics / Q000276:immunology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007546:Isoquinolines / Q000494:pharmacology; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000628:therapy; D058990:Molecular Targeted Therapy / Q000379:methods; D010880:Piperidines; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors / Q000378:metabolism; D011687:Purines / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D052999:Quinazolinones / Q000494:pharmacology; D000069283:Rituximab / Q000008:administration & dosage / Q000494:pharmacology; D054852:Small Molecule Libraries / Q000494:pharmacology; D013449:Sulfonamides / Q000494:pharmacology; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018941:Antigens, CD19; D019086:Bridged Bicyclo Compounds, Heterocyclic; D007546:Isoquinolines; D010880:Piperidines; D019253:Proto-Oncogene Proteins c-bcl-2; D011687:Purines; D011720:Pyrazoles; D011743:Pyrimidines; D052999:Quinazolinones; D054852:Small Molecule Libraries; D013449:Sulfonamides; C551803:ibrutinib; D000069283:Rituximab; C586691:duvelisib; D003520:Cyclophosphamide; D011505:Protein-Tyrosine Kinases; D000077329:Agammaglobulinaemia Tyrosine Kinase; C000625949:BTK protein, human; D014740:Vidarabine; D000225:Adenine; C579720:venetoclax; C543332:obinutuzumab; C024352:fludarabine; C552946:idelalisib